Many of the ADHD medication shortages that have plagued the U.S. for the last two years have now been resolved, the Food and Drug Administration says. Yet some doctors and patients report they are ...
Asianet Newsable on MSN
Cingulate stock jumps overnight: US Patent Office clears ADHD drug filing ahead of May FDA catalyst
The FDA has set May 31 as the PDUFA target date to decide on Cingulate’s ADHD drug CTx-1301.
The US Food and Drug Administration (FDA) has accepted for priority review Otsuka Pharmaceutical’s new drug application (NDA) submitted for centanafadine, an investigational, once-daily ...
A commonly used ADHD medication is being recalled nationwide after failing lab tests. The medication, lisdexamfetamine dimesylate capsules, is the generic form of Vyvanse, a stimulant that improves ...
Add Yahoo as a preferred source to see more of our stories on Google. A commonly prescribed medication for attention-deficit hyperactivity disorder (ADHD) has been recalled nationwide after failing to ...
KANSAS CITY, Kan., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (CING) (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform ...
A large multicenter clinical trial led by King's College London with 150 children and adolescents has shown that a device cleared by the US FDA to treat ADHD is not effective in reducing symptoms. The ...
Kenvue, the American company that makes Tylenol, says the U.S. Food and Drug Administration should not make proposed changes to the product’s safety label to reflect research about a possible ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results